Gene · 64006
Papers4,423
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,423
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Experimental Identification of Cross-Reacting IgG Hotspots to Predict Existing Immunity Evasion of SARS-CoV-2 Variants by a New Biotechnological Application of Phage Display. | Viruses | 2023 | 38257758 | PubTator, text mining | PubMed |
| Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. | Viruses | 2023 | 38257752 | PubTator, text mining | PubMed |
| Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms. | Front Plant Sci | 2023 | 38239207 | PubTator, text mining | PubMed |
| Plant-expressed Zika virus envelope protein elicited protective immunity against the Zika virus in immunocompetent mice. | Sci Rep | 2023 | 38151523 | PubTator, text mining | PubMed |
| Functional features of a novel interferon-stimulated gene SHFL: a comprehensive review. | Front Microbiol | 2023 | 38149274 | PubTator, text mining | PubMed |
| Approaches to pandemic prevention - the chromatin vaccine. | Front Immunol | 2023 | 38143744 | PubTator, text mining | PubMed |
| The Antiviral Activity of the Lectin Griffithsin against SARS-CoV-2 Is Enhanced by the Presence of Structural Proteins. | Viruses | 2023 | 38140693 | PubTator, text mining | PubMed |
| Computational Analysis of CD46 Protein Interaction with SARS-CoV-2 Structural Proteins: Elucidating a Putative Viral Entry Mechanism into Human Cells. | Viruses | 2023 | 38140538 | PubTator, text mining | PubMed |
| Molecular Mimicry between SARS-CoV-2 Proteins and Human Self-Antigens Related with Autoimmune Central Nervous System (CNS) Disorders. | Microorganisms | 2023 | 38138047 | PubTator, text mining | PubMed |
| Human Endogenous Retrovirus-K (HML-2)-Related Genetic Variation: Human Genome Diversity and Disease. | Genes (Basel) | 2023 | 38136972 | PubTator, text mining | PubMed |
| Investigation of SARS-CoV-2 individual proteins reveals the in vitro and in vivo immunogenicity of membrane protein. | Sci Rep | 2023 | 38129491 | PubTator, text mining | PubMed |
| The value of serum neutralizing antibody in evaluating predictability of COVID-19 after recovery and the validation of vaccine. | BMC Infect Dis | 2023 | 38124038 | PubTator, text mining | PubMed |
| Transcriptomic analysis reveals impact of gE/gI/TK deletions on host response to PRV infection. | Virol J | 2023 | 38115115 | PubTator, text mining | PubMed |
| HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies. | Virus Evol | 2023 | 38107333 | PubTator, text mining | PubMed |
| Decoy peptides effectively inhibit the binding of SARS-CoV-2 to ACE2 on oral epithelial cells. | Heliyon | 2023 | 38107325 | PubTator, text mining | PubMed |
| Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. | RSC Adv | 2023 | 38077980 | PubTator, text mining | PubMed |
| Analysis, Modeling, and Target-Specific Predictions of Linear Peptides Inhibiting Virus Entry. | ACS Omega | 2023 | 38075802 | PubTator, text mining | PubMed |
| Development and evaluation of neutralizing antibodies for cross-protection against West Nile virus and Japanese encephalitis virus. | Infect Med (Beijing) | 2023 | 38073882 | PubTator, text mining | PubMed |
| Dual Effects of 3-epi-betulin from Daphniphyllum glaucescens in Suppressing SARS-CoV-2-Induced Inflammation and Inhibiting Virus Entry. | Int J Mol Sci | 2023 | 38069363 | PubTator, text mining | PubMed |
| An In-silico Approach to Design and Validate siRNA against Monkeypox Virus. | Curr Pharm Des | 2023 | 38062661 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64006/papers?page=11